Review of once-monthly oral ibandronate and the use thereof
An advisory board meeting of key opinion leaders was held in 2015 to discuss the clinical data on oral ibandronate in the treatment of postmenopausal osteoporosis. Boniva 150 mg (ibandronate) oral once-monthly is indicated for the treatment of osteoporosis in postmenopausal women, in order to red...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2017-08-01
|
| Series: | South African Family Practice |
| Subjects: | |
| Online Access: | https://safpj.co.za/index.php/safpj/article/view/4728 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | An advisory board meeting of key opinion leaders was held in 2015 to discuss the clinical data on oral ibandronate in the treatment of postmenopausal osteoporosis.
Boniva 150 mg (ibandronate) oral once-monthly is indicated for the treatment of osteoporosis in postmenopausal women, in order to reduce the risk of vertebral fractures.1 |
|---|---|
| ISSN: | 2078-6190 2078-6204 |